4-(4-{2-[(2S)-2-Hydroxy-3-(4-methanesulfonylamino-phenoxy)-propylamino]-ethyl}-phenylamino)-piperidine-1-carboxylic acid octylamide | 392625-07-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(4-{2-[(2S)-2-Hydroxy-3-(4-methanesulfonylamino-phenoxy)-propylamino]-ethyl}-phenylamino)-piperidine-1-carboxylic acid octylamide
• 英文别名: 4-[4-[2-[[(2S)-2-hydroxy-3-[4-(methanesulfonamido)phenoxy]propyl]amino]ethyl]anilino]-N-octylpiperidine-1-carboxamide
• CAS: 392625-07-9
• 化学式: C₃₂H₅₁N₅O₅S
• 分子量: 617.853
• InChiKey: WDFXCBHAQULOER-PMERELPUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  43
• 可旋转键数：
  19
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  140
• 氢给体数：
  5
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  4-[4-(2-aminoethyl)anilino]-N-octyl-1-piperidinecarboxamide 、 N-[4-[[(2S)-oxiran-2-yl]methoxy]phenyl]methanesulfonamide 以 chloroform methanol 为溶剂， 以to give the title compound (0.04 g, 0.064mmol)的产率得到4-(4-{2-[(2S)-2-Hydroxy-3-(4-methanesulfonylamino-phenoxy)-propylamino]-ethyl}-phenylamino)-piperidine-1-carboxylic acid octylamide
  参考文献：
  名称：

  Heterocyclic beta-3 adrenergic receptor agonists

  摘要：

  本发明提供了具有以下结构的I型化合物，其中，U、V、W、X和Y如前所定义，或其药学上可接受的盐，它们在治疗或抑制与胰岛素抵抗或高血糖相关的代谢性疾病（通常与肥胖或葡萄糖不耐受相关）、动脉粥样硬化、胃肠道疾病、神经遗传性炎症、青光眼、眼内压增高和频繁排尿方面非常有用；并且在治疗或抑制II型糖尿病方面特别有用。

  公开号：

  US06605618B2

文献信息

• Heterocyclic &bgr;-3 adrenergic receptor agonists
  申请人：Wyeth

  公开号：US06451814B1

  公开（公告）日：2002-09-17

  This invention provides compounds of Formula I having the structure U, V, W, X, and Y are as defined hereinbefore, or a pharmaceutically acceptable salt thereof, which are useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, glaucoma, ocular hypertension and frequent urination; and are particularly useful in the treatment or inhibition of type II diabetes.

  本发明提供I式化合物，其中U、V、W、X和Y的结构如前所定义，或其药学上可接受的盐，其用于治疗或抑制与胰岛素抵抗或高血糖相关的代谢紊乱（通常与肥胖或葡萄糖不耐症相关），动脉粥样硬化，胃肠道疾病，神经炎症，青光眼，眼压增高和频繁排尿；并且在治疗或抑制II型糖尿病方面特别有用。
• US6451814B1
  申请人：——

  公开号：US6451814B1

  公开（公告）日：2002-09-17
• US6605618B2
  申请人：——

  公开号：US6605618B2

  公开（公告）日：2003-08-12
• [EN] HETEROCYCLIC BETA-3 ADRENERGIC RECEPTOR AGONISTS<br/>[FR] AGONISTES DES BETA-3 RECEPTEURS ADRENERGIQUES HETEROCYCLIQUES
  申请人：AMERICAN HOME PROD

  公开号：WO2002006229A2

  公开（公告）日：2002-01-24

  This invetion provides compounds of Formula (1) having the structure (A), wherein U, V, W, X, and Y are as defined herinbefore, or a pharmaceutically acceptable salt thereof, which are useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, glaucoma, ocular hypertension and frequent urination; and are particularly useful in the treatment or inhibition of type II diabetes.
• Heterocyclic beta-3 adrenergic receptor agonists
  申请人：American Home Products Corporation

  公开号：US20020028832A1

  公开（公告）日：2002-03-07

  This invention provides compounds of Formula I having the structure 1 U, V, W, X, and Y are as defined hereinbefore, or a pharmaceutically acceptable salt thereof, which are useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, glaucoma, ocular hypertension and frequent urination; and are particularly useful in the treatment or inhibition of type II diabetes.

  这项发明提供了具有结构式I的化合物 1 其中U、V、W、X和Y如前文所定义， 或其药学上可接受的盐，用于治疗或抑制与胰岛素抵抗或高血糖相关的代谢紊乱（通常与肥胖或葡萄糖不耐受有关）、动脉粥样硬化、胃肠道疾病、神经炎症、青光眼、眼压增高和频繁排尿；特别适用于治疗或抑制2型糖尿病。